Ozempic and Wegovy: What People Really Experience on GLP-1 Medications

There is an enormous amount written about GLP-1 medications and almost none of it describes the day-to-day. The clinical literature reports averages. The advertising reports transformations. What is missing is the ordinary texture: what the first month feels like, what people worry about at three months, what happens at the plateau, and what it is like to stop. This article draws on first-person accounts from people taking these drugs. It is companion reading, not medical advice, and nothing here should be used to start, stop, change or source a prescription medicine.

What these medications are, briefly

GLP-1 receptor agonists imitate a gut hormone released after eating, which regulates appetite, blood sugar and the rate at which the stomach empties. Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight management. Tirzepatide, marketed as Mounjaro and Zepbound, acts on both the GLP-1 and GIP receptors. For most of their history these were weekly injections; oral options arrived recently, with an oral semaglutide tablet approved by the FDA at the end of 2025 and Eli Lilly's orforglipron following in 2026. Availability, licensed indications and branding all differ by country.

All of them are prescription medicines with real contraindications, and the decision to take one belongs between a person and their prescriber. What follows is not about whether to. It is about what people report once they have.

"Food noise" is the thing people did not expect

The most striking and most consistent theme in these accounts has nothing to do with the scales. People describe the disappearance of a constant background negotiation about food that they had never quite named until it stopped.

Contributors describe driving past a fast-food sign and simply not registering it. Leaving half a plate without deciding to. Forgetting, for the first time in decades, to think about lunch. Many describe this as the single most disorienting part of the experience, and several describe grieving it in a way that surprised them, because the negotiation had been a companion.

The other emotional note that comes up repeatedly is anger. People who spent twenty or thirty years being told they lacked willpower describe a specific fury on discovering that the problem responded to a weekly injection. "I was not weak. I was under-medicated" is a sentiment expressed in a hundred different ways.

The side effects, described honestly

Nausea is the one everyone has heard of and it is genuinely common. Accounts describe it as worst in the day or two after a dose and worst again after each dose increase, easing as the body adjusts to a given level. People describe learning to eat smaller amounts, to stop at the first sign of fullness rather than the usual point, and to avoid very fatty or very rich food on the days when nausea is at its peak.

Constipation comes up nearly as often as nausea and is discussed far less publicly. So does its opposite. Reflux, sulphurous burps, and a sensation of food sitting undigested for hours are all described with some frequency, and all follow logically from a drug that deliberately slows gastric emptying.

The more serious risks are rarer but real and are listed in the prescribing information for each drug: pancreatitis, gallbladder problems, and, in the US labelling, a boxed warning relating to thyroid C-cell tumours observed in rodents. Anyone with a personal or family history of medullary thyroid carcinoma or MEN2 is excluded from these medications. This is prescriber territory, not internet territory, and people who describe the best experiences are consistently the ones who reported symptoms early rather than pushing through.

The pattern that recurs in the accounts of people who struggled most: escalating the dose faster than their body tolerated, either because they were impatient or because supply gaps forced an irregular schedule.

The muscle question

A worry that has grown much louder in the last two years, and which appears in a great many accounts, is what proportion of the loss is fat and what proportion is lean tissue. Rapid weight loss by any means — medication, surgery, severe restriction — takes muscle along with fat, and muscle is harder to rebuild than it was to lose, particularly for people over fifty.

Contributors describe this playing out as unexpected weakness: struggling with a suitcase, finding stairs harder despite weighing less, and in a few cases a visible loss of shape in the arms and legs that they had not anticipated. The people who report the best experiences describe two things, both of which they say their clinicians raised with them: deliberately increasing protein intake, and adding resistance exercise rather than only walking. What the right amounts are is an individual matter for a clinician or dietitian, and the accounts vary widely on specifics.

The plateau, and what people make of it

Weight loss on these medications is not linear and it does not continue indefinitely. The trial data show the curve flattening, and people describe hitting a plateau anywhere from a few months in to a year or more, often well short of the number they had in their heads.

This is where accounts diverge most sharply. Some people describe reaching a plateau and making peace with it, noting improvements in blood pressure, blood sugar, joint pain, sleep apnoea or mobility that mattered more to them than the remaining stones. Others describe genuine distress at stopping short of a goal weight, and describe the temptation to escalate the dose beyond what they were tolerating well.

Several contributors make the same observation in different words: the medication removed the appetite, but it did not by itself remove the reason they had been eating. People who describe the most durable results tend to describe having done something about that separately.

Stopping is the part nobody plans for

This is the least discussed and possibly the most important theme in the accounts. People stop for many reasons: cost, supply, side effects, pregnancy, insurance changes, or reaching a goal and assuming the job was done.

What they describe is the return of appetite, often within weeks, and often as a shock. The food noise comes back. The trial evidence points the same way: in the extension of the STEP 1 trial, participants who came off semaglutide regained a large majority of the weight they had lost within about a year. Contributors describe the psychological weight of this as heavier than the physical, particularly for people who had experienced regain before and had allowed themselves to believe this time was structurally different.

Clinicians increasingly frame obesity as a chronic condition and these medications as ongoing treatment rather than a course. Whether that framing is right is contested, and it collides hard with the reality of what these drugs cost. But the people who describe the least distressing experiences are, without exception, the ones who understood before they started that stopping would have consequences and had thought through what they would do.

Cost, supply, and the grey market

A large part of what people actually talk about is money. Access varies enormously: some are covered by insurance or a national health service, some pay several hundred a month, and some cycle on and off according to what they can afford, which is exactly the pattern that produces the worst side-effect experiences and the sharpest regain.

Cost pressure drives people toward compounded and telehealth-sourced versions, and toward products bought without a prescription. Compounded preparations are not FDA-approved finished products and are not equivalent to the licensed drug; products sold outside a regulated pharmacy channel may be neither the drug nor the dose they claim. Accounts from people who went that route include some that were uneventful and some that were not. It is not a saving worth making blind, and it is worth discussing openly with a prescriber rather than concealing.

What people say they wish they had known

• That the quieting of "food noise" would be the defining experience, and that it would feel stranger than expected.
• That nausea peaks after each dose increase and eases, and that rushing the titration is the main avoidable mistake.
• That constipation is extremely common and worth raising early rather than enduring.
• That protein and resistance training matter, because the loss takes muscle as well as fat.
• That the curve flattens, and that the plateau is not a failure.
• That appetite returns after stopping, and that this is expected rather than a personal collapse.
• That the drug addresses appetite, not the reasons behind eating.

Reading the accounts in full

If what you want is not a summary but the actual texture of it — fifty people describing their own months, including the ones for whom it did not work — our Weight Loss & Obesity shelf collects first-person accounts by topic, including The GLP-1 Revolution: Ozempic & Wegovy Stories. For people whose route was surgical, Sleeved for Success: Gastric Sleeve Stories and Bypassing Obesity: Gastric Bypass Transformation Stories cover the same ground from a different direction. Where the medication was prescribed for diabetes rather than weight, Diabetes & Blood Sugar is the relevant shelf.

Every volume includes a section given to the accounts that did not resolve well. A collection in which everybody succeeded would be advertising, not testimony.

Sources and further reading

• The approved prescribing information for the specific product you have been prescribed, which lists contraindications, warnings and the full side-effect profile. Your pharmacist can give you this.
• Published trial evidence on weight regain after discontinuation, including the STEP 1 trial extension.
• Your own prescriber, dietitian or diabetes team, whose guidance is specific to you and overrides anything written here.

Healing Stories Network publishes anthologies of first-person patient testimony. This article describes what people report experiencing on these medications. It is companion reading and is not medical advice, and it is not a recommendation to take, avoid, adjust or obtain any medicine. Read about who writes and checks our articles.